Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions

International Journal of Molecular Sciences

Volumn 14, Issue 10, 2013, Pages 19731-19762

  Gnoni, Antonio ^a   Licchetta, Antonella ^a   Scarpa, Aldo ^b   Azzariti, Amalia ^c   Brunetti, Anna Elisabetta ^c   Simone, Gianni ^c   Nardulli, Patrizia ^c   Santini, Daniele ^d   Aieta, Michele ^e   Delcuratolo, Sabina ^c   Silvestris, Nicola ^c  

^a VITO FAZZI HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Carcinogenesis; micro RNAs; Oncogenes; Pancreatic adenocarcinoma; Precursor lesions

Indexed keywords

BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPAMINE; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MICRORNA; MUCIN 1; MUCIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN P53; PROTEIN PATCHED 1; SARIDEGIB; SMAD4 PROTEIN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

APOPTOSIS; CANCER CELL; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RESISTANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CDKN2A GENE; CELL CYCLE REGULATION; CELL SURVIVAL; CPG ISLAND; DESMOPLASIA; DISTANT METASTASIS; DNA DAMAGE; DNA METHYLATION; EGFR GENE; ENZYME INHIBITION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FANCC GENE; FANCG GENE; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; GENETIC PREDISPOSITION; HISTONE MODIFICATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LOSS OF FUNCTION MUTATION; METASTASIS POTENTIAL; MICROSATELLITE INSTABILITY; MUCINOUS CYSTIC NEOPLASM; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; ONCOLOGICAL PARAMETERS; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; POINT MUTATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; CARCINOGENESIS; HUMANS; PANCREATIC NEOPLASMS;

EID: 84885139501     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141019731     Document Type: Review

References (191)

1. Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605-1617.
2. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics 2012. CA Cancer J. Clin. 2012, 62, 10-29.
3. Parkin, D.M.; Bray, F.I.; Devesa, S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001, 37, S4-S66.
4. Neoptolemos, J.P.; Stocken, D.D.; Bassi, C.; Ghaneh, P.; Cunningham, D.; Goldstein, D.; Padbury, R.; Moore, M.J.; Gallinger, S.; Mariette, C.; et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 2010, 304, 1073-1081.
5. Vincent, A.; Herman, J.; Schulick, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607-620.
6. Lowenfels, A.B.; Maisonneuve, P. Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20, 197-209.
7. Koorstra, J.B.; Hustinx, S.R.; Offerhaus, G.J.; Maitra, A. Pancreatic carcinogenesis. Pancreatology 2008, 8, 110-125.
8. Brat, D.J.; Lillemoe, K.D.; Yeo, C.J.; Warfield, P.B.; Hruban, R.H. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol. 1998, 22, 163-169.
9. Hruban, R.H.; Maitra, A.; Goggins, M. Update on pancreatic intraepithelial neoplasia. Int. J. Clin. Exp. Pathol. 2008, 1, 306-316.
10. Sergeant, G.; Vankelecom, H.; Gremeaux, L.; Topal, B. Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat. Rev. Clin. Oncol. 2009, 6, 580-586.
11. Hermann, P.C.; Mueller, M.T.; Heeschen, C. Pancreatic cancer stem cells-insights and perspectives. Expert Opin. Biol. Ther. 2009, 9, 1271-1278.
12. Bhagwandin, V.J.; Shay, J.W. Pancreatic cancer stem cells: Fact or fiction? Biochim. Biophys. Acta 2009, 1792, 248-259.
13. Simeone, D.M. Pancreatic cancer stem cells: Implications for the treatment of pancreatic cancer. Clin. Cancer Res. 2008, 14, 5646-5648.
14. Stelow, E.B.; Adams, R.B.; Moskaluk, C.A. The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms. Am. J. Surg. Pathol. 2006, 30, 36-41.
15. Iacobuzio-Donahue, C.A.; Wilentz, R.E.; Argani, P.; Yeo, C.J.; Cameron, J.L.; Kern, S.E. Dpc4 protein in mucinous cystic neoplasms of the pancreas: Frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am. J. Surg. Pathol. 2000, 24, 1544-1548.
16. Hruban, R.H.; Pitman, M.B.; Klimstra, D.S. In Tumors of the Pancreas; Firminger, H.I., Ed.; Atlas of Tumor Pathology Series 4; American Registry of Pathology and Armed Forces Institute of Pathology: Washington, DC, USA, 2007.
17. Hruban, R.H.; Adsay, N.V.; Albores-Saavedra, J.; Compton, C.; Garrett, E.; Goodman, S.N. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 2001, 25, 579-586.
18. Yamaguchi. K.; Yokohata, K.; Noshiro, H.; Chijiiwa, K.; Tanaka, M. Mucinous cystic neoplasm of the pancreas or intraductal papillary-mucinous tumour of the pancreas. Eur. J. Surg. 2000, 166, 141-148.
19. Cubilla, A.L.; Fitzgerald, P.J. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 1976, 36, 2690-2698.
20. Hruban, R.H.; Wilentz, R.E.; Kern, S.E. Genetic progression in the pancreatic ducts. Am. J. Pathol. 2000, 156, 1821-1825.
21. Day, J.D.; Digiuseppe, J.A.; Yeo, C. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum. Pathol. 1996, 27, 119-124.
22. Wilentz, R.E.; Geradts, J.; Maynard, R. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression. Cancer Res. 1998, 58, 4740-4744.
23. Rosty, C.; Geradts, J.; Sato, N.; Wilentz, R.E.; Roberts, H.; Sohn, T.; Cameron, J.L.; Yeo, C.J.; Hruban, R.H.; Goggins, M. p16 inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am. J. Surg. Pathol. 2003, 27, 1495-1501.
24. Caldas, C.; Hahn, S.A.; da Costa, L.T.; Redston, M.S.; Schutte, M.; Seymour, A.B.; Weinstein, C.L.; Hruban, R.H.; Yeo, C.J.; Kern, S.E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 1994, 8, 27-32.
25. Ueki, T.; Toyota, M.; Sohn, T.; Yeo, C.J.; Issa, J.P.; Hruban, R.H. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000, 60, 1835-1839.
26. Wilentz, R.E.; Iacobuzio-Donahue, C.A.; Argani, P. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000, 60, 2002-2006.
27. Bassi, C.; Sarr, M.G.; Lillemoe, K.D.; Reber, H.A. Natural history of intraductal papillary mucinous neoplasms (IPMN): Current evidence and implications for management. J. Gastrointest. Surg. 2008, 12, 645-650.
28. Kloppel, G.; Kosmahl, M.; Luttges, J. Intraductal neoplasms of the pancreas: Cystic and common. Pathologe 2005, 26, 31-36.
29. Zamboni, G.; Scarpa, A.; Bogina, G. Mucinous cystic tumors of the pancreas: Clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am. J. Surg. Pathol. 1999, 23, 410-422.
30. Fukushima, N.; Mukai, K. Pancreatic neoplasms with abundant mucus production: Emphasis on intraductal papillary-mucinous tumors and mucinous cystic tumors. Adv. Anat. Pathol. 1999, 6, 65-77.
31. Su, G.H.; Hruban, R.H.; Bansal, R.K. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol. 1999, 154, 1835-1840.
32. Maire, F.; Hammel, P.; Terris, B. Intraductal papillary and mucinous pancreatic tumour: A new extracolonic tumour in familial adenomatous polyposis. Gut 2002, 51, 446-449.
33. Tanaka, M.; Chari, S.; Adsay, V.; Fernandez-Del Castillo, C.; Falconi, M.; Shimizu, M.; Yamaguchi, K.; Yamao, K.; Matsuno, S. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006, 6, 17-32.
34. Niedergethmann, M.; Grutzmann, R.; Hildebrand, R.; Dittert, D.; Aramin, N.; Franz, M.; Dobrowolsky, F.; Post, S.; Saeger, H.D. Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): A 10-year experience. World J. Surg. 2008, 32, 2253-2260.
35. Ban, S.; Naitoh, Y.; Ogawa, F. Intraductal papillary mucinous neoplasm (IPMN) of the gastric-type with focal nodular growth of the arborizing papillae: A case of high-grade transformation of the gastric-type IPMN. Virchows. Arch. 2006, 449, 112-116.
36. Adsay, N.V.; Pierson, C.; Sarkar, F. Colloid (mucinous non cystic) carcinoma of the pancreas. Am. J. Surg. Pathol. 2001, 25, 26-42.
37. Adsay, N.V.; Merati, K.; Basturk, O.; Iacpbuzio-Donahue, C.; Levi, E.; Cheng, J.D.; Sarkar, F.H.; Hruban, R.H.; Klimsta, D.S. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: Delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am. J. Surg. Pathol. 2004, 28, 839-848.
38. Adsay, N.V.; Adair, C.F.; Heffess, C.S. Intraductal oncocytic papillary neoplasms of the pancreas. Am. J. Surg. Pathol. 1996, 20, 980-994.
39. Ban, S.; Naitoh, Y.; Mino-Kenudson, M. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: Its histopathologic difference between 2 major types. Am. J. Surg. Pathol. 2006, 30, 1561-1569.
40. Crippa, S.; Partelli, S.; Tamburrino, D.; Falconi, M. The natural history of a branch-duct intraductal papillary mucinous neoplasm of the pancreas. Surgery 2012, doi:10.1016/j.surg.2012.11.003.
41. Dal Molin, M.; Matthaei, H.; Wu, J.; Blackford, A.; Debeljak, M.; Rezaee, N.; Wolfgang, C.L.; Butturini, G.; Salvia, R.; Bassi, C.; et al. Clinicopathological correlates of activating GNAS mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas. Ann. Surg. Oncol. 2013, in press.
42. Sessa, F.; Solcia, E.; Capella, C.; Bonato, M.; Scarpa, A.; Zamboni, G.; Pellegata, N.S.; Ranzani, G.N.; Rickaert, F.; Kloppel, G. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: An investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows. Arch. 1994, 425, 357-367.
43. Biankin, A.V.; Biankin, S.A.; Kench, J.G. Aberrant p16 (INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut 2002, 50, 861-868.
44. Sato, N.; Ueki, T.; Fukushima, N.; Lacobuzio-Donahue, C.A.; Yeo, C.J.; Cameron, J.L.; Hruban, R.H.; Goggins, M. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002, 123, 365-372.
45. House, M.G.; Guo, M.; Iacobuzio-Donahue, C.; Herman, J.G. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003, 24, 193-198.
46. Pitman, M.B.; Michaels, P.J.; Deshpande, V. Cytological and cyst fluid analysis of small (< or = 3 cm) branch duct intraductal papillary mucinous neoplasms adds value to patient management decisions. Pancreatology 2008, 8, 277-284.
47. Sakorafas, G.H.; Sarr, M.G.; van de Velde, C.J. Intraductal papillary mucinous neoplasms of the pancreas: A surgical perspective. Surg. Oncol. 2005, 14, 155-178.
48. Sho, M.; Nakajima, Y.; Kanehiro, H.; Hisanaga, M.; Nishio, K.; Nagao, M.; Ikeda, N.; Kanokogi, H.; Yamada, T.; Nakano, H. Pattern of recurrence after resection for intraductal papillary mucinous tumors of the pancreas. World J. Surg. 1998, 22, 874-878.
49. Raut, C.P.; Cleary, K.R.; Staerkel, G.A.; Abruzzese, J.L.; Wolff, R.A.; Lee, J.H.; Vauthey, J.N.; Lee, J.E.; Pisters, P.W.; Evans, D.B. Intraductal papillary mucinous neoplasms of the pancreas: Effect of invasion and pancreatic margin status on recurrence and survival. Ann. Surg. Oncol. 2006, 13, 582-594.
50. Reddy, R.P.; Smyrk, T.C.; Zapiach, M.; Levy, M.J.; Pearson, R.K.; Clain, J.E.; Farnell, M.B.; Sarr, M.G.; Chari, S.T. Pancreatic mucinous cystic neoplasm defined by ovarian stroma: Demographics, clinical features, and prevalence of cancer. Clin. Gastroenterol. Hepatol. 2004, 2, 1026-1031.
51. Campbell, F.; Azadeh, B. Cystic neoplasms of the exocrine pancreas. Histopathology 2008, 52, 539-551.
52. Zamboni, G.; Capelli, P.; Pesci, A.; Brighenti, A. Pathology of Cystic Tumor. In Imaging of the Pancreas: Cystic and Rare Tumors; Procacci, C., Megibow, A.J., Eds.; Springer-Verlag: Berlin, Germany, 2003; pp. 9-30.
53. Erdogan, D.; Lamers, W.H.; Offerhaus, G.J.; Busch, O.R.; Gouma, D.J.; van Gulik, T.M. Cystadenomas with ovarian stroma in liver and pancreas: An evolving concept. Dig. Surg. 2006, 23, 186-191.
54. Flejou, J.F.; Boulange, B.; Bernades, P.; Belghiti, J.; Henin, D. p53 protein expression and DNA ploidy in cystic tumors of the pancreas. Pancreas 1996, 13, 247-252.
55. Bartsch, D.; Bastian, D.; Barth, P. K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. Ann. Surg. 1998, 228, 79-86.
56. Wenig, B.M.; Albores-Saavedra, J.; Buetow, P.C.; Heffess, C.S. Pancreatic mucinous cystic neoplasm with sarcomatous stroma: A report of three cases. Am. J. Surg. Pathol. 1997, 21, 70-80.
57. Longnecker, D.S.; Adler, G.; Hruban, R.H.; Kloppel, G. Intraductal Papillary-Mucinous Neoplasms of the Pancreas. In Pathology and Genetics of Tumours of the Digestive System. WHO Classification of Tumours; Hamilton, S.R., Aaltonen, L.A., Eds.; IARC Press: Lyon, France, 2000; pp. 237-240.
58. Fernandez-del Castillo, C.; Targarona, J.; Thayer, S.P.; Rattner, D.W.; Brugge, W.R.; Warshaw, A.L. Incidental pancreatic cysts: Clinicopathologic characteristics and comparison with symptomatic patients. Arch. Surg. 2003, 138, 427-433.
59. Sahani, D.V.; Kadavigere, R.; Saokar, A.; Fernandez-Del Castillo, C.; Brugge, W.R.; Hahn, P.F. Cystic pancreatic lesions: A simple imaging-based classification system for guiding management. Radiographics 2005, 25, 1471-1484.
60. Takaori, K.; Tanigawa, N. Laparoscopic pancreatic resection: The past, present, and future. Surg. Today 2007, 37, 535-545.
61. Almoguera, C.; Shibata, D.; Forrester, K.; Martin, J.; Arnheim, N.; Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53, 549-554.
62. Hruban, R.H.; van Mansfeld, A.D.; Offerhaus, G.J.; van Weering, D.H.; Allison, D.C.; Goodman, S.N.; Kensler, T.W.; Bose, K.K.; Cameron, J.L.; Bos, J.L. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol. 1993, 143, 545-554.
63. Lohr, M.; Kloppel, G.; Maisonneuve, P. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: A meta-analysis. Neoplasia 2005, 7, 17-23.
64. Schneider, G.; Schmid, R.M. Genetic alterations in pancreatic carcinoma. Mol. Cancer 2003, 2, 15.
65. Tada, M.; Omata, M.; Kawai, S.; Saisho, H.; Ohto, M.; Saiki, R.K.; Sninsky, J.J. Detection of Ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 1993, 53, 2472-2474.
66. Jimeno, A.; Hidalgo, M. Molecular biomarkers: Their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol. Cancer Ther. 2006, 5, 787-796.
67. End, D.W.; Smets, G.; Todd, A.V. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001, 61, 131-137.
68. Van Cutsem, E.; van de Velde, H.; Karasek, P. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004, 22, 1430-1438.
69. Laheru, D.; Shah, P.; Rajeshkumar, N.V. Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS), Salirasib in pancreatic cancer. Invest. New Drugs 2012, 30, 2391-2399.
70. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501.
71. Schonleben, F.; Qiu, W.L.; Ciau, N.T.; Ho, D.J.; Li, X.J.; Allendorf, J.D.; Remotti, H.E.; Su, G.H. PIK-3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin. Cancer Res. 2006, 12, 3851-3855.
72. Asano, T.; Yao, Y.; Zhu, J.; Li, D.; Abbruzzese, J.L.; Reddy, S.A. The PI 3-kinase/Akt signalling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004, 23, 8571-8580.
73. Feig, L.A. Ral GTPases: Approaching their 15 min of fame. Trends Cell Biol. 2003, 13, 419-425.
74. Lim, K.H.; O'Hayer, K.; Adam, S.J.; Kendall, S.D.; Campbell, P.M.; Der, C.J.; Counter, C.M. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr. Biol. 2006, 16, 2385-2394.
75. Elghazi, L.; Weiss, A.J.; Barker, D.J.; Callaghan, J.; Staloch, L.; Sandgren, E.P. Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology 2009, 136, 1091-1103.
76. Stanger, B.Z.; Stiles, B.; Lauwers, G.Y.; Bardeesy, N.; Mendoza, M.; Wang, Y. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005, 8, 185-195.
77. Ying, H.; Elpekc, K.G.; Vinjamoori, A.; Zimmermanh, S.M.; Chua, G.C.; Yan, H.; Fletcher-Sananikone, E.; Zhang, H.; Liu, Y.; Wang, W.; et al. Pten is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 2011, 1, 158-169.
78. Thayer, S.P.; di Magliano, M.P.; Heiser, P.W.; Nielsen, C.M.; Roberts, D.J.; Lauwers, G.Y.; Qi, Y.P.; Gysin, S.; Fernandez-del Castillo, C.; Yajnik, V.; et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425, 851-856.
79. Berman, D.M.; Karhadkar, S.S.; Maitra, A.; Montes de Oca, R.; Gerstenblith, M.R.; Briggs, K.; Parker, A.R.; Shimada, Y.; Eshleman, J.R.; Watkins, D.N.; et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425, 846-851.
80. Bailey, J.M.; Swanson, B.J.; Hamada, T.; Eggers J.P.; Caffery, T.; Ouellette, M.M.; Hollingsworth, M.A. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 2008, 14, 5995-6004.
81. Yauch, R.L.; Gould, S.E.; Scales, S.J.; Tang, T.; Tian, H.; Ahn, C.P.; Marshall, D.; Fu, L.; Januario, T.; Kallop, D.; et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455, 406-410.
82. Feldmann, G.; Dhara, S.; Fendrich, V.; Bedja, D.; Beaty, R.; Mullendore, M.; Karikari, C.; Alvarez, H.; Iacobuzio-Donahue, C.; Jimeno, A.; et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 2007, 67, 187-219.
83. Hidalgo, M.; Maitra, A. The hedgehog pathway and pancreatic cancer. N. Engl. J. Med. 2009, 361, 2094-2096.
84. Nolan-Stevaux, O.; Lau, J.; Truitt, M.L.; Chu, G.C.; Hebrok, M.; Fernandez-Zapico, M.E.; Hanahan, D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009, 23, 24-36.
85. Onishi, H.; Morifuji, Y.; Kai, M.; Suyama, K.; Iwasaki, H.; Katano, M. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Sci. 2012, 103, 1272-1279.
86. Tremblay, M.R.; Lescarbeau, A.; Grogan, M.J.; Tan, E.; Lin, G.; Austad, B.C.; Yu, L.C.; Behnke, M.L.; Nair, S.J.; Hagel, M.; et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J. Med. Chem. 2009, 52, 4400-4418.
87. Sjolund, J.; Manetopoulos, C.; Stockhausen, M.T.; Axelson, H. The Notch pathway in cancer: Differentiation gone awry. Eur. J. Cancer 2005, 41, 2620-2629.
88. Wang, Z.; Zhang, Y.; Li, Y.; Banerjee, S.; Liao, J.; Sarkar, F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 2006, 5, 483-493.
89. Miyamoto, Y.; Maitra, A.; Ghosh, B.; Zechner, U.; Argani, P.; Iacobuzio-Donahue, C.A.; Sriuranpong, V.; Iso, T.; Meszoely, I.M.; Wolfe, M.S.; et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3, 565-576.
90. Miwa, W.; Yasuda, J.; Murakami, Y.; Yashima, K.; Sugano, K.; Sekine, T.; Kono, A.; Egawa, S.; Yamaguchi, K.; Hayashizaki, Y.; et al. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem. Biophys. Res. Commun. 1996, 225, 968-974.
91. Cheng, J.Q.; Ruggeri, B.; Klein, W.M.; Sonoda, G.; Altomare, D.A.; Watson, D.K.; Testa, J.R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA 1996, 93, 3636-3641.
92. Wallrapp, C.; Muller-Pillasch, F.; Solinas-Toldo, S.; Lichter, P.; Friess, H.; Buchler, M.; Fink, T.; Adler, G.; Gress, T.M. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res. 1997, 57, 3135-3139.
93. Hezel, A.F. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006, 13, 1218-1249.
94. Gerdes, B. Tumor-suppressing pathways in cystic pancreatic tumors. Pancreas 2003, 13, 42-48.
95. Russo, A.A.; Tong, L.; Lee, J.O.; Jeffrey, P.D.; Pavletich, N.P. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 1998, 395, 237-243.
96. De vos Nederveen Cappel, W.H.; Lagendijk, M.A.; Lamers, C.B.; Morreau, H.; Vasen, H.F. Surveillance for familial pancreatic cancer. Scand. J. Gastroenterol. Suppl. 2003, 329, 94-99.
97. Muller, P.A.; Vousden, K.H. p53 mutations in cancer. Nat. Cell. Biol. 2013, 15, 2-8.
98. Redston, M.S.; Caldas, C.; Seymour, A.B.; Hruban, R.H.; da Costa, L.; Yeo, C.J.; Kern, S.E. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994, 54, 3025-3033.
99. Weiss, R.H.; Marshall, D.; Howard, L.; Corbacho, A.M.; Cheung, A.T.; Sawai, E.T. Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21 (Waf1/Cip1). Cancer Lett. 2003, 189, 39-48.
100. Garcea, G.; Neal, C.P.; Pattenden, C.J.; Steward, W.P.; Berry, D.P. Molecular prognostic markers in pancreatic cancer: A systematic review. Eur. J. Cancer 2005, 41, 2213-2236.
101. Hahn, S.A.; Schutte, M.; Hoque, A.T.; Moskaluk, C.A.; da Costa, L.T.; Rozenblum, E.; Weinstein, C.L.; Fischer, A.; Yeo, C.J.; Hruban, R.H.; et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271, 350-353.
102. Massague, J.; Blain, S.W.; Lo, R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103, 295-309.
103. Gaspar, N.J.; Li, L.Y.; Kapoun, A.M.; Medicherla, S.; Reddy, M.; Li, G.; O'Young, G.; Quon, D.; Henson, M.; Damm, D.L.; et al. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol. Pharmacol. 2007, 72, 152-161.
104. Maitra, A.; Kern, S.E.; Hruban, R.H. Molecular pathogenesis of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20, 211-226.
105. Han, H.J.; Yanagisawa, A.; Kato, Y.; Park, J.G.; Nakamura, Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res. 1993, 53, 5087-5089.
106. Goggins, M.; Offerhaus, G.J.; Hilgers, W.; Griffin, C.A.; Shekher, M.; Tang, D.; Sohn, T.A.; Yeo, C.J.; Kern, S.E.; Hruban, R.H. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am. J. Pathol. 1998, 152, 1501-1507.
107. Marcus, V.A.; Madlensky, L.; Gryfe, R. Immunohistochemistry for hMLH1 and hMSH2: A practical test for DNA mismatch repairdeficient tumors. Am. J. Surg. Pathol. 1999, 23, 1248-1255.
108. Tomaszewska, R.; Okon, K.; Stachura, J. Expression of the DNA mismatch repair proteins (hMLH1 and hMSH2) in infiltrating pancreatic cancer and its relation to some phenotypic features. Pol. J. Pathol. 2003, 54, 31-37.
109. Couch, F.J.; Johnson, M.R.; Rabe, K.; Boardman, L.; McWilliams, R.; de Andrade, M.; Petersen, G. Germ line fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005, 65, 383-386.
110. Van der Heijden, M.S.; Yeo, C.J.; Hruban, R.H.; Kern, S.E. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 2003, 63, 2585-2588.
111. Hahn, S.A.; Greenhalf, B.; Ellis, I.; Sina-Frey, M.; Rieder, H.; Korte, B.; Gerdes, B.; Kress, R.; Ziegler, A.; Raeburn, J.A.; et al. BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl. Cancer Inst. 2003, 95, 214-221.
112. Gallmeier, E.; Calhoun, E.S.; Rago, C.; Brody, J.R.; Cunningham, S.C.; Hucl, T.; Gorospe, M.; Kohli, M.; Lengauer, C.; Kern, S.E. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 2006, 130, 2145-2154.
113. Micalizzi, D.S.; Ford, H.L. Epithelial-mesenchymal transition in development and cancer. Future Oncol. 2009, 5, 1129-1143.
114. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119, 1420-1428.
115. Thiery, J.P.; Acloque, H.; Huang, R.Y.J.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871-890.
116. Yang, A.D.; Camp, E.R.; Fan, F.; Shen, L.; Gray, M.J.; Liu, W.; Somcio, R.; Bauer, T.W.; Wu, Y.; Hicklin, D. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res. 2006, 66, 46-51.
117. Gidekel Friedlander, S.Y.; Chu, G.C.; Snyder, E.L.; Girnius, N.; Dibelius, G.; Crowley, D.; Vasile, E.; Depinho, R.A.; Jacks, T. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 2009, 16, 379-389.
118. Guerra, C.; Schuhmacher, A.J.; Canamero, M.; Grippo, P.J.; Verdaguer, L.; Perez-Gallego, L.; Dubus, P.; Sandgren, E.P.; Barbacid, M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11, 291-302.
119. Maier, H.J.; Schmidt-Strassburger, U.; Huber, M.A.; Wiedemann, E.M.; Beug, H.; Wirth, T. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 2010, 295, 214-228.
120. Baumgart, S.; Ellenrieder, V.; Fernandez-Zapico, M.E. Oncogenic transcription factors: Cornerstones of inflammation-linked pancreatic carcinogenesis. Gut 2013, 62, 310-316.
121. Singh, S.; Sadanandam, A.; Singh, R.K. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 2007, 26, 453-467.
122. Denz, A.; Pilarsky, C.; Muth, D.; Ruckert, F.; Saeger, H.D.; Grutzmann, R. Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J. Surg. Res. 2010, 160, 29-34.
123. Jin, Z.Q.; Zhi, F.C.; Chen, X.Q.; Wang, Y.D. Expression of macrophage migration inhibition factor in pancreatic carcinoma tissue. Di Yi Jun Yi Da Xue Xue Bao 2004, 24, 1301-1303.
124. Funamizu, N.; Hu, C.; Lacy, C.; Schetter, A.; Zhang, G.; He, P.; Gaedcke, J.; Ghadimi, M.B.; Ried, T.; Yfantis, H.G.; et al. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int. J. Cancer 2012, doi:10.1002/ijc.27736.
125. Yang, A.D.; Fan, F.; Camp, E.R.; van Buren, G.; Liu, W.; Somcio, R.; Gray, M.J.; Cheng, H.; Hoff, P.M.; Ellis L.M. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 2006, 12, 4147-4153.
126. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A.; Ali, S.; Abbruzzese, J.L.; Gallick, G.E.; Sarkar, F. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69, 2400-2407.
127. Shah, A.N.; Summy, J.M.; Zhang, J.; Park, S.; Parikh, N.; Gallick, G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14, 3629-3637.
128. Buck, E.; Eyzaguirre, A.; Barr, S.; Thompson, S.; Sennello, R.; Young, D.; Iwata, K.K.; Gibson, N.W.; Cagnoni, P.; Haley, J.D. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 2007, 6, 532-541.
129. Menke, A.; Adler, G. TGFbeta-induced fibrogenesis of the pancreas. Int. J. Gastrointest. Cancer 2002, 31, 41-46.
130. Wu, K.; Zeng, J.; Li, L.; Fan, J.; Zhang, D.; Xue, Y.; Zhu, G.; Yang, L.; Wang, X.; He, D. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol. Rep. 2010, 23, 1545-1552.
131. Nguyen, C.; Liang, G.; Nguyen, T.T.; Tsao-Wei, D.; Groshen, S.; Lubbert, M.; Zhou, J.H.; Benedict, W.F.; Jones, P.A. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J. Natl. Cancer Inst. 2001, 93, 1465-1472.
132. Jones, P.A. The DNA methylation paradox. Trends Genet. 1999, 15, 34-37.
133. Bird, A.P. CpG-rich islands and the function of DNA methylation. Nature 1986, 321, 209-213.
134. Baylin, S.; Bestor, T.H. Altered methylation patterns in cancer cell genomes: Cause or consequence? Cancer Cell 2002, 1, 299-305.
135. Mikkelsen, T.S.; Ku, M.; Jaffe, D.B.; Issac, B.; Lieberman, E.; Giannoukos, G.; Alvarez, P.; Brockman, W.; Kim, T.K.; Koche, R.P. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007, 448, 553-560.
136. Squazzo, S.L.; O'Geen, H.; Komashko, V.M.; Krig, S.R.; Jin, V.X.; Jang, S.W.; Margueron, R.; Reinberg, D.; Green, R.; Farnham, P.J. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 2006, 16, 890-900.
137. Ku, M.; Koche, R.P.; Rheinbay, E.; Mendenhall, E.M.; Endoh, M.; Mikkelsen, T.S.; Presser, A.; Nusbaum, C.; Xie, X.; Chi, A.S. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. 2008, 4, e1000242.
138. Clarke, M.F.; Fuller, M. Stem cells and cancer: Two faces of Eve. Cell 2006, 124, 1111-1115.
139. Kim, J.; Woo, A.J.; Chu, J.; Snow, J.W.; Fujiwara, Y.; Kim, C.G.; Cantor, A.B.; Orkin, S.H. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010, 143, 313-324.
140. Trumpp, A.; Wiestler, O.D. Mechanisms of disease: Cancer stem cells-Targeting the evil twin. Nat. Clin. Pract. Oncol. 2008, 5, 337-347.
141. Sharma, S.V.; Lee, D.Y.; Li, B.; Quinlan, M.P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M.A. A chromatinmediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141, 69-80.
142. Easwaran, H.; Johnstone, S.E.; van Neste, L.; Ohm, J.; Mosbruger, T.; Wang, Q.; Aryee, M.J.; Joyce, P.; Ahuja, N.; Weisenberger, D.; et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 2012, 22, 837-849.
143. Teschendorff, A.E.; Menon, U.; Gentry-Maharaj, A.; Ramus, S.J.; Weisenberger, D.J.; Shen, H.; Campan, M.; Noushmehr, H.; Bell, C.G.; Maxwell, A.P. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010, 20, 440-446.
144. Zhang, L.; Gao, J.; Li, Z.; Gong, Y. Neuronal pentraxin II (NPTX2) is frequently down-regulated by promoter hypermethylation in pancreatic cancers. Dig. Dis. Sci. 2012, 57, 2608-2614.
145. Aghdassi, A.; Sendler, M.; Guenther, A.; Mayerle, J.; Behn, C.O.; Heidecke, C.D.; Friess, H.; Buchler, M.; Evert, M.; Lerch, M.M.; et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 2012, 61, 439-448.
146. Cai, H.H.; Yue-Ming, S.; Yi, M.; Wen-Tao, G.; Quan, P.; Jie, Y.; Han-Lin, Z. Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines. Hepatobiliary Pancreat. Dis. Int. 2011, 10, 95-100.
147. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350.
148. Wang, J.; Yi, X.; Tang, H. Direct quantification of microRNA at low picomolar level in sera of glioma patients using a competitive hybridization followed by amplified voltammetric detection. Anal. Chem. 2012, 84, 6400.
149. Baker, M.B.; Bao, G.; Searles, C.D. In vitro quantification of specific microRNA using molecular beacons. Nucleic Acids Res. 2012, 40, e13.
150. Lee, E.J.; Gusev, Y.; Jiang, J. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 2007, 120, 1046.
151. Roldo, C.; Missiaglia, E.; Hagan, J.P.; Falconi, M.; Capelli, P.; Bersani, S.; Calin, G.A.; Volinia, S.; Liu, C.G.; Scarpa, A.; et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24, 4677-4684.
152. Bloomston, M.; Frankel, W.L.; Petrocca, F.; Volinia, S.; Alder, H.; Hagan, J.P.; Liu, C.G.; Bhatt, D.; Taccioli, C.; Croce, M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297, 1901-1908.
153. Wang, J.; Chen, J.; Chang, P. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. 2009, 2, 807.
154. Zhang, Y.; Li, M.; Wang, H.; Fisher, W.E.; Lin, P.H.; Yao, Q.; Chen, C. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by realtime PCR analysis. World J. Surg. 2009, 33, 698-709.
155. Habbe, N.; Koorstra, J.B.; Mendell, J.T. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther. 2009, 8, 340.
156. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R.M.; Okamoto, A.; Yokota, J.; Tanaka, T.; et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9, 189.
157. Yu, S.; Lu, Z.; Liu, C.; Meng, Y.; Ma, Y.; Zhao, W.; Liu, J.; Chen, J. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010, 70, 6015.
158. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10, 704.
159. Lin, F.; Wang, X.; Jie, Z. Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16. J. Huazhong Univ. Sci. Technol. Med. Sci. 2011, 31, 509.
160. Laurila, E.M.; Sandstrom, S.; Rantanen, L.M.; Autio, R.; Kallioniemi, A. Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes Cancer 2012, 51, 557.
161. Dillhoff, M.; Liu, J.; Frankel, W. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008, 12, 2171.
162. Tsuda, N.; Ishiyama, S.; Li, Y.; Yoannides, C.G.; Abruzzese, J.L.; Chang, D.Z. Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. Clin. Cancer Res. 2006, 12, 6557.
163. Ma, Y.; Yu, S.; Zhao, W. miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett. 2010, 298, 150.
164. Paterson, E.L.; Kolesnikoff, N.; Gregory, P.A.; Bert, A.G.; Khew-Goodall, Y.; Goodall, G.J. The micro-RNA-200 family regulates epithelial to mesenchymal transition. Sci. World J. 2008, 8, 901.
165. Park, J.K.; Lee, E.J.; Esau, C. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009, 38, e190.
166. Iwagami, Y.; Eguchi, H.; Nagano, H.; Akita, H.; Hama, N.; Wada, H.; Kawamoto, K.; Kobayashi, S.; Tomokuni, A.; Tomimaru, Y.; et al. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br. J. Cancer 2013, 10, 1038.
167. Mace, T.A.; Collins, A.L.; Wojcik, S.E.; Croce, C.M.; Lesinski, G.B.; Bloomston, M. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J. Surg Res. 2013, 18, S0022-S4804.
168. Torrisani, J.; Bournet, B.; du Rieu, M.C.; Bouisson, M.; Souque, A.; Escourrou, J.; Buscail, L.; Cordelier, P. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum. Gene Ther. 2009, 20, 831.
169. Feig, C.; Gopinathan, A.; Neesse, A.; Chan, D.S.; Cook, N.; Tuveson, D.A. The pancreas cancer microenvironment. Clin. Cancer Res. 2012, 18, 4266-4276.
170. Singh, M.; Lima, A.; Molina, R.; Hamilton, P.; Clermont, A.C.; Devasthali, V. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28, 585-593.
171. Gopinathan, A.; Tuveson, D.A. The use of GEM models for experimental cancer therapeutics. Dis. Model. Mech. 2008, 1, 83-86.
172. Hingorani, S.R.; Wang, L.; Multani, A.S.; Combs, C.; Deramaudt, T.B.; Hruban, R.H. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7, 469-483.
173. Apte, M.V.; Haber, P.S.; Applegate, T.L.; Norton, I.D.; McCaughan, G.W.; Korsten, M.A. Periacinar stellate shaped cells in rat pancreas: Identification, isolation, and culture. Gut 1998, 43, 128-133.
174. Omary, M.B.; Lugea, A.; Lowe, A.W.; Pandol, S.J. The pancreatic stellate cell: A star on the rise in pancreatic diseases. J. Clin. Invest. 2007, 117, 50-59.
175. Erkan, M.; Adler, G.; Apte, M.V.; Bachem, M.G.; Buchholz, M.; Detlefsen, S. StellaTUM: Current consensus and discussion on pancreatic stellate cell research. Gut 2012, 61, 172-178.
176. Vonlaufen, A.; Joshi, S.; Qu, C.; Phillips, P.A.; Xu, Z.; Parker, N.R. Pancreatic stellate cells: Partners in crime with pancreatic cancer cells. Cancer Res. 2008, 68, 2085-2093.
177. Xu, Z.; Vonlaufen, A.; Phillips, P.A.; Fiala-Beer, E.; Zhang, X.; Yang, L. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 2010, 177, 2585-2596.
178. Lonardo, E.; Frias-Aldeguer, J.; Hermann, P.C.; Heeschen, C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 2012, 11, 1282-1290.
179. Hamada, S.; Masamune, A. Takikawa, T.; Suzuki, N.; Kikuta, K.; Hirota, M. Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2012, 421, 349-354.
180. Neesse, A.; Michl, P.; Frese, K.K.; Feig, C.; Cook, N.; Jacobetz, M.A. Stromal biology and therapy in pancreatic cancer. Gut 2011, 60, 861-868.
181. Olive, K.P.; Jacobetz, M.A.; Davidson, C.J.; Gopinathan, A.; McIntyre, D.; Honess, D. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324, 1457-1461.
182. Tian, H.; Callahan, C.A.; DuPree, K.J.; Darbonne, W.C.; Ahn, C.P.; Scales, S.J. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl. Acad. Sci. USA 2009, 106, 4254-4259.
183. Vismodegib and Gemcitabine Hydrochloride in Treating Patients with Advanced Pancreatic Cancer. Available online: http://clinicaltrials.gov/show/NCT01195415 (accessed on 13 September 2013).
184. Gemcitabine Hydrochloride with or without Vismodegib in Treating Patients with Recurrent or Metastatic Pancreatic Cancer. Available online: http://clinicaltrials.gov/ct2/show/study/NCT01064622 (accessed on 13 September 2013).
185. A Study Evaluating IPI-926 in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer. Available online: http://clinicaltrials.gov/show/NCT01130142 (accessed on 13 September 2013).
186. Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS). Available online: http://clinicaltrials.gov/show/NCT01096732 (accessed on 13 September 2013).
187. Infante, J.R.; Matsubayashi, H.; Sato, N.; Tonascia, J.; Klein, A.P.; Riall, T.A. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 2007, 25, 319-325.
188. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12, 1317-1324.
189. Von Hoff, D.D.; Ramanathan, R.K.; Borad, M.J.; Laheru, D.A.; Smith, L.S.; Wood, T.E. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J. Clin. Oncol. 2011, 29, 4548-4554.
190. Lowenfels, A.B.; Maisonneuve, P.; Cavallini, G.; Ammann, R.W.; Lankisch, P.G.; Andersen, J.R. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 1993, 328, 1433-1437.
191. Dodson, L.F.; Hawkins, W.G.; Goedegebuure, P. Potential targets for pancreatic cancer immunotherapeutics. Immunother 2011, 3, 517-537.